IMBCR is dedicated to advance the treatment of myeloma by connecting possibility through scientific innovation leading to personalized and continuous optimized patient care.
With APP Help, Cancer Clinical Trials No Longer a ‘Last-Ditch’ Option
Cranial Nerve Palsy May Be Present After Cilta-Cel for Multiple Myeloma
Trajectory of Symptom Severity Aids Follow-Up in Head and Neck Cancer Treatment
Nurse-Driven Orders May Expedite Tocilizumab Administration for CRS